Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9248571 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3BCHETSHR | |
| SCHEMBL1371362 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3BCHETSHR | |
| SCHEMBL1339058 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3BCHETSHR | |
| SCHEMBL10126134 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3BCHETSHR | |
| SCHEMBL1339056 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3BCHETSHR | |
| SCHEMBL7385512 | 0.78 | CYP1A2 (0.38) | SLC6A2SLC6A4SLC6A3CYP1A2CYP2C19 | |
| SCHEMBL7379057 | 0.78 | CYP1A2 (0.38) | SLC6A2SLC6A4SLC6A3CYP1A2CYP2C19 | |
| SCHEMBL10591424 | 0.78 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3TSHRSLC1A3 | |
| SCHEMBL10591418 | 0.78 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3TSHRSLC1A3 | |
| SCHEMBL30999474 | 0.77 | BCHE (0.36) | SLC6A2SLC6A4SLC6A3BCHECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| WO-2010042851-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-2138482-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113391-A1 | BICYCLIC HETEROCYCLIC COMPOUND | P2RY12, P2RY4, P2RY1 | SLC6A2 2656/4885SLC6A4 1294/4885SLC6A3 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.